Entecavir Global Market Report 2025

Entecavir is an antiviral medication used for the treatment of chronic hepatitis B. It works by inhibiting the replication of the hepatitis B virus, which helps lower the viral load. This, in turn, reduces the risk of severe liver damage and complications such as cirrhosis or liver cancer.

The primary forms of entecavir are tablets and oral solution. Entecavir tablets are taken orally and are prescribed for managing chronic hepatitis B (CHB) infection. These tablets are utilized for a range of purposes, including hepatitis B treatment, liver transplantation, and other related conditions. They are available through various distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The entecavir market research report is one of a series of new reports from The Business Research Company that provides entecavir market statistics, including the entecavir industry's global market size, regional shares, competitors with an entecavir market share, detailed entecavir market segments, market trends and opportunities, and any further data you may need to thrive in the entecavir industry. This entecavir market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The entecavir market size has grown steadily in recent years. It will grow from $0.71 billion in 2024 to $0.74 billion in 2025 at a compound annual growth rate (CAGR) of 3.9%. The growth in the historic period can be attributed to rise in incidence of hepatitis B, rise in awareness on liver related diseases, increase in focus on personalized medicine, growth in online shopping for medications, and increase in availability of entecavir.

The entecavir market size is expected to see steady growth in the next few years. It will grow to $0.87 billion in 2029 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to rising initiatives to combat liver diseases, increasing adoption of digital healthcare solutions, increasing healthcare infrastructure, rising health insurance coverage, and increasing demand for anti viral medications. Major trends in the forecast period include integration of genetic testing, integration of advanced diagnostic tools, advancements in personalized medicine, adoption of combination therapies, and advancements in monitoring techniques.

The forecast of 4.1% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. hepatitis B treatment programs by increasing the cost of nucleoside analog active pharmaceutical ingredients and antiviral tablet formulations sourced from India and China, potentially reducing medication adherence and raising liver disease management costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of liver diseases is expected to drive the growth of the entecavir market in the coming years. Liver diseases encompass a variety of conditions that impair liver function, including infections, genetic disorders, and lifestyle-related issues such as fatty liver, hepatitis, cirrhosis, and liver cancer. The rise in liver diseases is primarily attributed to factors such as viral hepatitis (HBV and HCV), increasing obesity rates, alcohol abuse, and metabolic disorders. Entecavir, an antiviral drug, supports liver disease patients by effectively inhibiting the replication of the hepatitis B virus, reducing viral load, improving liver function, and lowering the risk of cirrhosis and liver cancer. This ultimately helps manage chronic hepatitis B infections and prevents further liver damage. For example, in June 2024, the Cancer Council Victoria reported that 617 individuals were diagnosed with liver cancer in 2022, with 67.9% of cases affecting males. Additionally, the Liver Foundation projected that around 3,000 people are diagnosed with hepatocellular carcinoma (HCC) annually. Therefore, the rising incidence of liver diseases is driving the growth of the entecavir market.

The increasing prevalence of hepatitis B is also expected to boost the entecavir market. Hepatitis B is a viral infection that affects the liver, causing symptoms such as jaundice, fatigue, and abdominal pain. If untreated, it can lead to chronic liver disease or liver cancer. The rise in hepatitis B cases is linked to factors such as unprotected sexual contact, needle sharing, mother-to-child transmission during childbirth, and insufficient vaccination coverage in certain regions. Entecavir treats hepatitis B by inhibiting the replication of the hepatitis B virus (HBV) DNA, reducing viral load, and preventing liver damage. For instance, in January 2025, the UK Health Security Agency reported that approximately 270,000 people in the UK were living with hepatitis B in 2022, and the number of diagnosed cases is expected to double by 2030. Consequently, the growing prevalence of hepatitis B is driving the growth of the entecavir market.

Companies in the entecavir market are advancing clinical trials and innovative drug development for chronic hepatitis B treatment, aiming to improve efficacy and treatment outcomes while reducing resistance and enhancing long-term viral suppression. Clinical trials are essential for evaluating the safety and effectiveness of new treatments. For example, in October 2024, Aligos Therapeutics Inc., a US-based biotechnology company, initiated a phase 2 clinical trial for ALG-000184, a capsid assembly modulator being developed for hepatitis B treatment. ALG-000184 works by disrupting the formation of the capsid, the protective shell around a virus's genetic material. The ongoing study is assessing the long-term effects of ALG-000184, either alone or in combination with entecavir (sold as Baraclude), in patients with chronic hepatitis B. Preliminary results indicate that the combination of ALG-000184 and entecavir led to more significant reductions in viral load compared to entecavir alone, with ALG-000184 maintaining similar effectiveness regardless of its use alongside entecavir. The virus remained suppressed throughout the study in both HBeAg-positive and HBeAg-negative patients.

Major players in the entecavir market are Bristol-Myers Squibb Company, GSK plc, Teva Pharmaceutical Industries Ltd., Qingfeng Pharmaceutical Group, Aurobindo Pharma Ltd., ScinoPharm Taiwan Ltd., Dr. Reddy's Laboratories Ltd., Cipla Inc., Zhejiang Huahai Pharmaceuticals Co. Ltd., Qianjin Group, Genix Pharma Ltd., Dawnrays Pharmaceutical Holidings Ltd., Zhejiang Ausun Pharmaceutical Co. Ltd., Hunan Warrant Chiral Pharmaceutical Co. Ltd., Camber Pharmaceuticals Inc., Century Pharmaceuticals Ltd., Aligos Therapeutics Inc. , HRV Global Life Sceince, Solco Healthcare LLC, Accela ChemBio Inc.

Asia-Pacific was the largest region in the entecavir market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in entecavir report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Entecavir market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The entecavir market consists of sales of generic versions, branded formulations, combination therapies, antiviral drugs, injectable formulations and over-the-counter antiviral supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Entecavir Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on entecavir market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for entecavir ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The entecavir market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Tablets; Oral Solution
• 2) By Application: Hepatitis B Treatment; Liver Transplantation; Other Applications
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Tablets: Standard Dose Tablets; High Dose Tablets
• 2) By Oral Solution: Ready-to-Use Liquid Solution; Powder For Oral Solution
• Companies Mentioned: Bristol-Myers Squibb Company; GSK plc; Teva Pharmaceutical Industries Ltd.; Qingfeng Pharmaceutical Group; Aurobindo Pharma Ltd.; ScinoPharm Taiwan Ltd.; Dr. Reddy's Laboratories Ltd.; Cipla Inc.; Zhejiang Huahai Pharmaceuticals Co. Ltd.; Qianjin Group; Genix Pharma Ltd.; Dawnrays Pharmaceutical Holidings Ltd.; Zhejiang Ausun Pharmaceutical Co. Ltd.; Hunan Warrant Chiral Pharmaceutical Co. Ltd.; Camber Pharmaceuticals Inc.; Century Pharmaceuticals Ltd.; Aligos Therapeutics Inc. ; HRV Global Life Sceince; Solco Healthcare LLC; Accela ChemBio Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.